目的：探讨纤维蛋白原与乳腺癌新辅助化疗的疗效及Ki-67表达水平的相关性。方法：选取2008年7月至2018年12月在北京怀柔医院就诊的乳腺癌新辅助化疗患者72例，采用免疫组织化学法检测Ki-67的表达水平，使用纤维蛋白原测定试剂盒检测纤维蛋白原的水平。结果：新辅助化疗的72例患者，18例病理完全缓解（pCR），54例存在残留癌。pCR的患者化疗前血浆纤维蛋白原水平低于未达到pCR的患者，纤维蛋白原下降≥0.2 g·L^-1与pCR相关（P<0.05）。纤维蛋白原下降≥0.2 g·L^-1的患者无复发生存时间及总生存时间均长于纤维蛋白下降未达到0.2 g·L^-1或纤维蛋白原稳定及上升的患者。Ki-67高表达患者新辅助化疗前血浆纤维蛋白原水平高于Ki-67低表达的患者。结论：血浆纤维蛋白原下降≥0.2 g·L^-1可能是预测乳腺癌新辅助化疗pCR的指标之一，化疗前血浆纤维蛋白≥2.0 g·L^-1是乳腺癌患者Ki-67高表达的主要独立危险因素。

[1] KIM G Y, SUH J, JANG J H, et al. Genistein inhibits proliferation of BRCA1 mutated breast cancer cells:the GPR30-Akt axis as a potential target[J]. J Cancer Prev, 2019, 24(4):197-207.
[2] WU J, KONG R, TIAN S, et al. Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy[J]. Chin J Cancer Res, 2019, 31(6):878-891.
[3] BAA A K, NAIK R D, VANIDASSANE I, et al. unusual gastric metastasis in triple-negative (estrogen receptor/progesterone receptor/her2neu negative) gata-binding protein 3-positive breast cancer[J]. Indian J Nucl Med, 2020, 35(1):82-83.
[4] MAMET N, AMIR Y, LAVI E, et al. Discovery of tumoricidal DNA oligonucleotides by response-directed in vitro evolution[J]. Commun Biol, 2020, 3(1):29.
[5] LI L, ZHENG X, ZHOU Q, et al. Metabolomics-based discovery of molecular signatures for triple negative breast cancer in asian female population[J]. Sci Rep, 2020, 10(1):370.
[6] ROKUDAI S.High-throughput RNA interference screen targeting synthetic-lethal gain-of-function of oncogenic mutant TP53 in Triple-negative breast cancer[J]. Methods Mol Biol, 2020, 2108:297-303.
[7] UDDIN M M, GAIRE B, DEZA B, et al. interleukin-8-induced invasion assay in triple-negative breast cancer cells[J]. Methods Mol Biol, 2020, 2108:107-115.
[8] KONG B, LV Z D, XIA J, et al. DLC-3 suppresses cellular proliferation, migration, and invasion in triple-negative breast cancer by the Wnt/β-catenin pathway[J]. Int J Clin Exp Pathol, 2019, 12(4):1224-1232.
[9] 于秀艳, 万广财, 孙洪帅, 等.纤维蛋白原与乳腺癌预后关系的分析[J]. 吉林大学学报(医学版), 2019, 45(5):1092-1097.
[10] WANG Y T, AIRETI G, LIU C H, er al.D-dimer, fibrinogen elevated related influencing factors and the clinical features and prognosis of malignant solid tumou patientss[J]. Mod Oncol, 2018, 26(12):1921-1924.
[11] 李玉梅.血浆纤维蛋白原水平与乳腺癌新辅助化疗疗效及预后的相关性[J]. 现代肿瘤医学, 2020, 28(21):3722-3725.
[12] 王义华, 刘胜春.纤维蛋白原与乳腺癌新辅助化疗疗效相关性的研究进展[J]. 现代医学与健康研究, 2021, 5(1):118-120.
[13] SHI H, WANG X H, GU J W, et al. Development and validation of nomograms for predicting the prognosis of triple-negative breast cancer patients based on 379 chinese patients[J]. Cancer Manag Res, 2019, 11:10827-10839.
[14] WEN J, YANG Y, YE F, et al. The preoperative plasma brinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment[J]. Breast, 2015, 24(6):745-750.
[15] KWAAN H C, LINDHOLM P F.Fibrin and brinolysis in cancer[J]. Semin Thromb Hemost, 2019, 45(4):413-422.